Demographic and clinical characteristics, such as median age (65 years; IQR 57−70), advanced disease stage at diagnosis, predominantly adenocarcinoma histology, and a relatively high proportion of never smokers among the RET fusion-positive cohort were generally as expected for this patient population (3, 6). Here, RET is linked to adenocarcinoma.